Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours

Ellen Brenner(University of Tübingen), Barbara F. Schörg(Siemens (Germany)), Fatima Ahmetlić(Helmholtz Zentrum München), Thomas Wieder(University of Tübingen), Franz J. Hilke(University of Tübingen), Nadine Simon(University of Tübingen), Christopher Schroeder(University of Tübingen), German Demidov(University of Tübingen), Tanja Riedel(Helmholtz Zentrum München), Birgit Fehrenbacher(University of Tübingen), Martin Schaller(University of Tübingen), Andrea Forschner(University of Tübingen), Thomas Eigentler(University of Tübingen), Heike Niessner(University of Tübingen), Tobias Sinnberg(University of Tübingen), Katharina Böhm(University of Tübingen), Nadine Hömberg(Helmholtz Zentrum München), Heidi Braumüller(University of Tübingen), Daniel Dauch(German Cancer Research Center), Stefan Zwirner, Lars Zender(German Cancer Research Center), Dominik Sonanini(Siemens (Germany)), Albert Geishauser(Helmholtz Zentrum München), Jürgen Bauer(University of Tübingen), Martin Eichner(University of Tübingen), Katja J. Jarick(University of Würzburg), Andreas Beilhack(University of Würzburg), Saskia Biskup(CeGaT (Germany)), Dennis Döcker(CeGaT (Germany)), Dirk Schadendorf(German Cancer Research Center), Leticia Quintanilla‐Martínez(University of Tübingen), Bernd J. Pichler(Siemens (Germany)), Manfred Kneilling(Siemens (Germany)), Ralph Mocikat(Helmholtz Zentrum München), Martin Röcken(German Cancer Research Center)
Nature Communications
March 12, 2020
Cited by 130Open Access
Full Text

Abstract

Abstract Immune checkpoint blockade (ICB)-based or natural cancer immune responses largely eliminate tumours. Yet, they require additional mechanisms to arrest those cancer cells that are not rejected. Cytokine-induced senescence (CIS) can stably arrest cancer cells, suggesting that interferon-dependent induction of senescence-inducing cell cycle regulators is needed to control those cancer cells that escape from killing. Here we report in two different cancers sensitive to T cell-mediated rejection, that deletion of the senescence-inducing cell cycle regulators p16 Ink4a /p19 Arf ( Cdkn2a ) or p21 Cip1 ( Cdkn1a ) in the tumour cells abrogates both the natural and the ICB-induced cancer immune control. Also in humans, melanoma metastases that progressed rapidly during ICB have losses of senescence-inducing genes and amplifications of senescence inhibitors. Metastatic cells also resist CIS. Such genetic and functional alterations are infrequent in metastatic melanomas regressing during ICB. Thus, activation of tumour-intrinsic, senescence-inducing cell cycle regulators is required to stably arrest cancer cells that escape from eradication.


Related Papers

No related papers found

Powered by citation graph analysis